Phase IIa trial of DB 959 in patients with type 2 diabetes mellitus and dyslipidaemia.
Latest Information Update: 27 Nov 2012
At a glance
- Drugs T3D 959 (Primary)
- Indications Dyslipidaemias; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors T3D Therapeutics
Most Recent Events
- 17 Jan 2012 Planned initiation date changed to 1 Jun 2012.
- 16 Aug 2011 New trial record